# **ACTG Study at CROI Links Integrase Inhibitor Regimens to Higher Obesity and Cardiometabolic Disease Risk**
## **Introduction**
At the 2024 Conference on Retroviruses and Opportunistic Infections (CROI), a significant study from the AIDS Clinical Trials Group (ACTG) shed light on potential health risks associated with integrase strand transfer inhibitors (INSTIs), a widely used class of antiretroviral therapy (ART) for people living with HIV (PLWH). The findings suggest that INSTIs may contribute to weight gain and increase the risk of obesity-related cardiometabolic diseases. These results have important implications for the long-term management of HIV and the selection of ART regimens.
## **Background on Integrase Inhibitors and HIV Treatment**
INSTIs have become a mainstay in the treatment of HIV due to their potent antiviral activity, favorable tolerability, and high resistance barrier. Commonly used INSTIs include:
– **Dolutegravir (DTG)**
– **Bictegravir (BIC)**
– **Raltegravir (RAL)**
– **Elvitegravir (EVG)/cobicistat**
Compared to older ART regimens, INSTIs offer improved virologic suppression with fewer drug interactions. However, emerging data suggest that they may be associated with significant weight gain and metabolic complications.
## **Key Findings from the ACTG Study**
At CROI 2024, researchers presented new findings from an ACTG study analyzing the metabolic outcomes of people living with HIV who initiated INSTI-based therapy. The study followed individuals over several years and compared changes in weight, body mass index (BMI), and markers of cardiometabolic health.
### **Weight Gain and Obesity Risk**
– Participants on INSTI-based regimens experienced **significantly greater weight gain** compared to those on non-INSTI regimens.
– The risk of developing **clinical obesity (BMI ≥30 kg/m²)** was notably higher in the INSTI group.
– Dolutegravir and bictegravir were linked to the highest weight increases among the INSTIs studied.
### **Cardiometabolic Disease Risk**
– Individuals who gained the most weight also exhibited **increased insulin resistance**, a key risk factor for type 2 diabetes.
– Higher rates of **dyslipidemia (abnormal cholesterol levels)** were observed among INSTI users.
– Elevated **blood pressure and waist circumference**, both indicators of cardiovascular disease risk, were more common in those taking INSTIs.
## **Potential Mechanisms Behind INSTI-Associated Weight Gain**
The exact reasons why INSTIs contribute to weight gain and metabolic complications remain under investigation, but several hypotheses have been proposed:
– **Changes in Energy Metabolism**: INSTIs may influence fat accumulation by altering mitochondrial function and lipid metabolism.
– **Effects on Appetite Regulation**: Some studies suggest that INSTIs could affect neurohormonal pathways involved in hunger and energy balance.
– **Differential Impact by Demographics**: Women and Black individuals have been observed to experience disproportionately higher weight gain with INSTIs, indicating potential genetic or hormonal influences.
## **Clinical Implications and Future Considerations**
The findings from the ACTG study highlight the importance of monitoring weight and metabolic health in patients receiving INSTI-based ART. Clinicians should consider the following when prescribing these medications:
– **Baseline Weight and Metabolic Risk**: Patients with existing obesity or metabolic disorders may require closer monitoring or alternative ART options.
– **Regular Screening**: Lipid levels, glucose metabolism, and blood pressure should be routinely assessed in patients on INSTIs.
– **Lifestyle Interventions**: Encouraging physical activity and healthy dietary habits can help mitigate weight gain and associated risks.
– **Potential ART Modifications**: In select cases, switching to an alternative regimen with a lower weight gain profile may be considered.
## **Conclusion**
The findings from the ACTG study at CROI 2024 add to the growing body of evidence that INSTI-based regimens, while highly effective in controlling HIV, may lead to increased risks of obesity and cardiometabolic diseases. As the global HIV population ages, balancing viral suppression with long-term metabolic health will be crucial. Further research is needed to better understand the mechanisms behind these effects and to develop strategies to optimize ART while minimizing metabolic risks.
By integrating these new insights into clinical practice, healthcare providers can help ensure that people living with HIV receive antiretroviral therapy that not only suppresses the virus but also promotes overall health and well-being.
—
**References**
– Presentation from the AIDS Clinical Trials Group (ACTG) at CROI 2024
– Recent studies on integrase inhibitor-associated weight gain
– Guidelines for antiretroviral therapy and metabolic health considerations